vs

Side-by-side financial comparison of LINDBLAD EXPEDITIONS HOLDINGS, INC. (LIND) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $183.2M, roughly 1.1× LINDBLAD EXPEDITIONS HOLDINGS, INC.). LINDBLAD EXPEDITIONS HOLDINGS, INC. runs the higher net margin — -12.9% vs -62.0%, a 49.2% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 23.3%). LINDBLAD EXPEDITIONS HOLDINGS, INC. produced more free cash flow last quarter ($3.5M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 9.2%).

Lindblad Expeditions is an expedition travel company headquartered in New York, NY. The company currently offers expedition cruises to destinations on all seven continents aboard 15 ships with capacities ranging from 28 to 150 guests.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

LIND vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$183.2M
LIND
Growing faster (revenue YoY)
RARE
RARE
+2.6% gap
RARE
25.9%
23.3%
LIND
Higher net margin
LIND
LIND
49.2% more per $
LIND
-12.9%
-62.0%
RARE
More free cash flow
LIND
LIND
$104.2M more FCF
LIND
$3.5M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
9.2%
LIND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LIND
LIND
RARE
RARE
Revenue
$183.2M
$207.3M
Net Profit
$-23.6M
$-128.6M
Gross Margin
40.3%
Operating Margin
-3.0%
-54.7%
Net Margin
-12.9%
-62.0%
Revenue YoY
23.3%
25.9%
Net Profit YoY
6.0%
3.5%
EPS (diluted)
$-0.45
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIND
LIND
RARE
RARE
Q4 25
$183.2M
$207.3M
Q3 25
$240.2M
$159.9M
Q2 25
$167.9M
$166.5M
Q1 25
$179.7M
$139.3M
Q4 24
$148.6M
$164.6M
Q3 24
$206.0M
$139.5M
Q2 24
$136.5M
$147.0M
Q1 24
$153.6M
$108.8M
Net Profit
LIND
LIND
RARE
RARE
Q4 25
$-23.6M
$-128.6M
Q3 25
$1.2M
$-180.4M
Q2 25
$-8.5M
$-115.0M
Q1 25
$1.2M
$-151.1M
Q4 24
$-25.0M
$-133.2M
Q3 24
$22.5M
$-133.5M
Q2 24
$-24.7M
$-131.6M
Q1 24
$-4.0M
$-170.7M
Gross Margin
LIND
LIND
RARE
RARE
Q4 25
40.3%
Q3 25
48.2%
Q2 25
45.6%
Q1 25
48.3%
Q4 24
42.5%
Q3 24
46.7%
Q2 24
39.2%
Q1 24
45.0%
Operating Margin
LIND
LIND
RARE
RARE
Q4 25
-3.0%
-54.7%
Q3 25
15.0%
-106.9%
Q2 25
2.6%
-64.8%
Q1 25
5.9%
-102.6%
Q4 24
-5.1%
-74.3%
Q3 24
14.3%
-94.6%
Q2 24
-6.0%
-79.1%
Q1 24
5.1%
-151.9%
Net Margin
LIND
LIND
RARE
RARE
Q4 25
-12.9%
-62.0%
Q3 25
0.5%
-112.8%
Q2 25
-5.1%
-69.0%
Q1 25
0.6%
-108.5%
Q4 24
-16.9%
-80.9%
Q3 24
10.9%
-95.7%
Q2 24
-18.1%
-89.5%
Q1 24
-2.6%
-156.8%
EPS (diluted)
LIND
LIND
RARE
RARE
Q4 25
$-0.45
$-1.28
Q3 25
$0.00
$-1.81
Q2 25
$-0.18
$-1.17
Q1 25
$0.00
$-1.57
Q4 24
$-0.45
$-1.34
Q3 24
$0.36
$-1.40
Q2 24
$-0.48
$-1.52
Q1 24
$-0.10
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIND
LIND
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$256.7M
$421.0M
Total DebtLower is stronger
$662.7M
Stockholders' EquityBook value
$-284.5M
$-80.0M
Total Assets
$980.0M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIND
LIND
RARE
RARE
Q4 25
$256.7M
$421.0M
Q3 25
$261.8M
$202.5M
Q2 25
$200.9M
$176.3M
Q1 25
$188.9M
$127.1M
Q4 24
$183.9M
$174.0M
Q3 24
$193.9M
$150.6M
Q2 24
$168.1M
$480.7M
Q1 24
$177.7M
$112.3M
Total Debt
LIND
LIND
RARE
RARE
Q4 25
$662.7M
Q3 25
$663.5M
Q2 25
$627.3M
Q1 25
$626.4M
Q4 24
$625.5M
Q3 24
$624.5M
Q2 24
$623.6M
Q1 24
$622.7M
Stockholders' Equity
LIND
LIND
RARE
RARE
Q4 25
$-284.5M
$-80.0M
Q3 25
$-256.6M
$9.2M
Q2 25
$-263.8M
$151.3M
Q1 25
$-252.2M
$144.2M
Q4 24
$-253.1M
$255.0M
Q3 24
$-226.9M
$346.8M
Q2 24
$-255.5M
$432.4M
Q1 24
$-227.4M
$140.3M
Total Assets
LIND
LIND
RARE
RARE
Q4 25
$980.0M
$1.5B
Q3 25
$976.5M
$1.2B
Q2 25
$936.5M
$1.3B
Q1 25
$908.8M
$1.3B
Q4 24
$876.9M
$1.5B
Q3 24
$889.8M
$1.5B
Q2 24
$858.3M
$1.6B
Q1 24
$868.0M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIND
LIND
RARE
RARE
Operating Cash FlowLast quarter
$14.4M
$-99.8M
Free Cash FlowOCF − Capex
$3.5M
$-100.8M
FCF MarginFCF / Revenue
1.9%
-48.6%
Capex IntensityCapex / Revenue
6.0%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$63.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIND
LIND
RARE
RARE
Q4 25
$14.4M
$-99.8M
Q3 25
$19.5M
$-91.4M
Q2 25
$29.2M
$-108.3M
Q1 25
$48.4M
$-166.5M
Q4 24
$1.7M
$-79.3M
Q3 24
$28.1M
$-67.0M
Q2 24
$18.6M
$-77.0M
Q1 24
$43.9M
$-190.7M
Free Cash Flow
LIND
LIND
RARE
RARE
Q4 25
$3.5M
$-100.8M
Q3 25
$11.9M
$-92.7M
Q2 25
$13.5M
$-110.7M
Q1 25
$35.0M
$-167.8M
Q4 24
$-8.2M
$-79.5M
Q3 24
$18.4M
$-68.6M
Q2 24
$11.2M
$-79.0M
Q1 24
$37.4M
$-193.9M
FCF Margin
LIND
LIND
RARE
RARE
Q4 25
1.9%
-48.6%
Q3 25
5.0%
-58.0%
Q2 25
8.0%
-66.5%
Q1 25
19.5%
-120.5%
Q4 24
-5.5%
-48.3%
Q3 24
8.9%
-49.2%
Q2 24
8.2%
-53.7%
Q1 24
24.4%
-178.2%
Capex Intensity
LIND
LIND
RARE
RARE
Q4 25
6.0%
0.5%
Q3 25
3.2%
0.8%
Q2 25
9.4%
1.5%
Q1 25
7.5%
1.0%
Q4 24
6.6%
0.1%
Q3 24
4.7%
1.2%
Q2 24
5.4%
1.4%
Q1 24
4.2%
3.0%
Cash Conversion
LIND
LIND
RARE
RARE
Q4 25
Q3 25
16.41×
Q2 25
Q1 25
41.69×
Q4 24
Q3 24
1.25×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LIND
LIND

Guest Ticket$96.5M53%
Landexperience$67.3M37%
Other Tour$19.4M11%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons